- Home
- PCB vs ACIU Comparison
PCB vs ACIU Comparison
Compare PCB & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PCB | ACIU |
|---|---|---|
| Founded | 2003 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 309.7M | 213.3M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | PCB | ACIU |
|---|---|---|
| Price | $23.82 | $3.01 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $24.50 | $10.00 |
| AVG Volume (30 Days) | 26.5K | ★ 1.4M |
| Earning Date | 01-29-2026 | 11-04-2025 |
| Dividend Yield | ★ 3.34% | N/A |
| EPS Growth | ★ 43.50 | N/A |
| EPS | ★ 2.41 | N/A |
| Revenue | ★ $107,743,000.00 | $5,482,957.00 |
| Revenue This Year | $21.55 | N/A |
| Revenue Next Year | $8.65 | $738.95 |
| P/E Ratio | $9.93 | ★ N/A |
| Revenue Growth | ★ 13.61 | N/A |
| 52 Week Low | $16.00 | $1.43 |
| 52 Week High | $24.04 | $4.00 |
Technical Indicators
Market Signals| Indicator | PCB | ACIU |
|---|---|---|
| Relative Strength Index (RSI) | 54.14 | 50.19 |
| Support Level | $23.03 | $2.87 |
| Resistance Level | $24.04 | $3.45 |
| Average True Range (ATR) | 0.61 | 0.31 |
| MACD | 0.10 | 0.03 |
| Stochastic Oscillator | 57.27 | 38.09 |
Price Performance
Historical ComparisonAbout PCB PCB Bancorp
PCB Bancorp is a bank holding company, which engages in the provision of consumer and commercial banking services. It provides Personal, Business, and Loan services, which provide banking, lending, and digital, tools, home loans, and others. Also, it offers a broad range of loans, deposits, and other products and services predominantly to small and middle-market businesses and individuals. The company provided it's services in Los Angeles and Orange Counties, California; Bellevue, Washington; and Atlanta, Georgia.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.